JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $17 price target.
August 14, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Sutro Biopharma and maintained a $17 price target.
The reiteration of a Market Outperform rating by JMP Securities indicates a positive outlook for Sutro Biopharma. The maintained price target of $17 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100